Beyond market averages, investors looking for exceptional returns turn to stock picking. Skillful choices in individual stocks have the power to substantially increase your wealth.
In the latest session, Pliant Therapeutics Inc (NASDAQ: PLRX) closed at $1.38 down -59.88% from its previous closing price of $3.44. In other words, the price has decreased by -$59.88 from its previous closing price. On the day, 19.39 million shares were traded.
Ratios:
For a deeper understanding of Pliant Therapeutics Inc’s stock, let’s take a closer look at its various ratios. For the most recent quarter (mrq), Quick Ratio is recorded 10.26 and its Current Ratio is at 10.26. In the meantime, Its Debt-to-Equity ratio is 0.17 whereas as Long-Term Debt/Eq ratio is at 0.17.
Wells Fargo Downgraded its Overweight to Equal Weight on February 10, 2025, whereas the target price for the stock was revised from $41 to $4.
Insider Transactions:
Additionally, insider trades can be beneficial to investors who want to learn what the management thinks about stock prices in the future. A recent insider transaction in this stock occurred on Jan 17 ’25 when Coulie Bernard sold 52,419 shares for $11.20 per share. The transaction valued at 587,150 led to the insider holds 430,517 shares of the business.
Cummings Keith Lamont sold 20,148 shares of PLRX for $225,680 on Jan 17 ’25. The Chief Financial Officer now owns 262,608 shares after completing the transaction at $11.20 per share. On Jan 17 ’25, another insider, Hull Hans, who serves as the Chief Business Officer of the company, sold 15,936 shares for $11.20 each. As a result, the insider received 178,501 and left with 211,558 shares of the company.
Stock Price History:
Over the past 52 weeks, PLRX has reached a high of $17.58, while it has fallen to a 52-week low of $2.43. The 50-Day Moving Average of the stock is -85.28%, while the 200-Day Moving Average is calculated to be -88.52%.
Shares Statistics:
A total of 60.85M shares are outstanding, with a floating share count of 52.66M. Insiders hold about 13.46% of the company’s shares, while institutions hold 97.36% stake in the company.
